
|Videos|June 19, 2014
Results of the ECOG E3805 Study
Author(s)Michael J. Morris
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Advertisement
Michael J. Morris, MD, GU Oncologists, Memorial Sloan Kettering Cancer Center, discusses the results of the ECOG E3805 study, which examined chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer.
Clinical Pearls:
- Patients in this trial were randomized to receive hormone therapy alone or hormone therapy plus 6 cycles of docetaxel.
- Median OS was 57.6 months in the hormone therapy plus docetaxel arm and 44.0 months in the hormone therapy arm.
- Median time to clinical progression was greater in the docetaxel plus hormone therapy arm (32.7 months) than the hormone therapy-only arm (19.8 months).
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5









































